95 related articles for article (PubMed ID: 8115415)
21. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
[TBL] [Abstract][Full Text] [Related]
22. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
Marin C; Chase TN
Eur J Pharmacol; 1993 Feb; 231(2):191-6. PubMed ID: 8095897
[TBL] [Abstract][Full Text] [Related]
23. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Gordon JH; Diamond BI
Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of neuroleptic-induced dopamine receptor supersensitivity by cyclo (Leu-Gly).
Bhargava HN; Ritzmann RF
Pharmacol Biochem Behav; 1980 Nov; 13(5):633-6. PubMed ID: 7443732
[TBL] [Abstract][Full Text] [Related]
25. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
Le Douarin C; Fage D; Scatton B
Life Sci; 1984 Jan; 34(4):393-9. PubMed ID: 6694528
[TBL] [Abstract][Full Text] [Related]
26. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
27. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
28. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.
Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
Eur J Pharmacol; 1982 Jun; 81(1):1-9. PubMed ID: 6889533
[TBL] [Abstract][Full Text] [Related]
29. Cyclo(Leu-Gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine: agonist binding to D2 dopamine receptors correlates with stereotypic behavior.
Lee JM; Fields JZ; Ritzmann RF
Life Sci; 1983; 33 Suppl 1():405-8. PubMed ID: 6229678
[TBL] [Abstract][Full Text] [Related]
30. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
[TBL] [Abstract][Full Text] [Related]
31. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
[TBL] [Abstract][Full Text] [Related]
32. Effect of cyclo(Leu-Gly) on reserpine-induced hypomotility and increases in cortical beta-adrenergic receptors.
Klein E; Lerer B; Newman M; Belmaker RH; Bhargava HN
Psychopharmacology (Berl); 1984; 83(1):76-8. PubMed ID: 6146157
[TBL] [Abstract][Full Text] [Related]
33. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
[TBL] [Abstract][Full Text] [Related]
34. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
Lynch MR
Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
[TBL] [Abstract][Full Text] [Related]
35. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
[TBL] [Abstract][Full Text] [Related]
36. Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity.
Marin C; Bonastre M; Tolosa E
Synapse; 1996 Jun; 23(2):89-93. PubMed ID: 8723713
[TBL] [Abstract][Full Text] [Related]
37. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
Jiang LH; Kasser RJ; Altar CA; Wang RY
J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
[TBL] [Abstract][Full Text] [Related]
38. Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor.
Fujita N; Nakahiro M; Fukuchi I; Saito K; Yoshida H
Brain Res; 1985 May; 333(2):231-6. PubMed ID: 3158374
[TBL] [Abstract][Full Text] [Related]
39. Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat.
Kinon BJ; Merson D; Kane JM
Psychopharmacology (Berl); 1984; 84(3):347-51. PubMed ID: 6440181
[TBL] [Abstract][Full Text] [Related]
40. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
Minematsu N
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
